^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Nasopharyngeal Carcinoma
    Drug:Loqtorzi (toripalimab-tpzi) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma

    Excerpt:
    ...Correlation between pre-treatment PD-L1 expression level and FFS`Correlation between pre-treatment PD-L1 expression level and OS`Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and PFS`Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and OS`Evaluate failure-free survival in the subgroup of age at diagnosis (year)`Evaluate failure-free survival in the subgroup of gender (male and female)`Evaluate failure-free survival in the subgroup of plasma Epstein-Barr virus DNA level`Evaluate failure-free survival in the subgroup of clinical stage`Evaluate the regression of tumor and parotid glands during radiotherapy...
    Trial ID:
    DIAMOND
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

    Excerpt:
    ...Investigate potential biomarkers including the expression level of AdenoSig in tumor tissues`Investigate potential biomarkers including the TMB in tumor tissues`Investigate potential biomarkers including the MSI status in relationship to efficacy outcomes`Investigate potential biomarkers including the expression level of PD-L1 in tumor tissues`Investigate potential biomarkers including the expression level of CD68 in tumor tissues`Investigate potential biomarkers including the expression level of A2aR in tumor tissues`Investigate potential biomarkers including the expression level of CD8 in tumor tissues...
    Trial ID:
    NCT05955105
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

    Excerpt:
    ...Overall Survival (OS)`Locoregional Relapse-Free Survival (LRRFS)`Distant Metastasis-Free Survival (DMFS)`Objective Response Rate （ORR）`Incidence rate of adverse events (AEs)`Correlation between the plasma EBV DNA level and PFS`Correlation between pre-treatment PD-L1 expression level and PFS`Correlation between the percentage of tumor-infiltrating lymphocytes (TILs) and PFS`Change of QoL (quality of life)`Number of subjects with major pathologic response (MPR)...
    Trial ID:
    NCT03925090
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    JAMA
    Title:

    Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial

    Published date:
    11/28/2023
    Excerpt:
    A consistent effect on overall survival, favoring toripalimab, was found in subgroups with high and low PD-L1 (programmed death–ligand 1) expression….The addition of toripalimab to chemotherapy as first-line treatment for RM-NPC provided statistically significant and clinically meaningful progression-free survival and overall survival benefits compared with chemotherapy alone, with a manageable safety profile. These findings support the use of toripalimab plus gemcitabine-cisplatin as the new standard of care for this patient population.
    Secondary therapy:
    cisplatin + gemcitabine
    DOI:
    10.1001/jama.2023.20181
    Trial ID:
    JUPITER-02